Evidence map›Paper›PMID 41440224›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Readability Optimization of Layperson Summaries in Urological Oncology Clinical Trials: Outcomes from the BRIDGE-AI 8 Study.

Ilicia Cano, Aalamnoor Pannu, Ethan Layne, Conner Ganjavi, Aditya Desai, Gus Miranda, Jie Cai, Vasileios Magoulianitis, Karan Gill, Gerhard Fuchs and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ilicia CanoUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Aalamnoor PannuUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Ethan LayneUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0009-0007-1639-5157
Conner GanjaviUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0001-9698-964X
Aditya DesaiUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Gus MirandaUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0001-6110-9024
Jie CaiUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Vasileios MagoulianitisUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Karan GillUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Gerhard FuchsUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Mihir DesaiUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Inderbir GillUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Giovanni E CacciamaniUSC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0002-8892-5539

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accessible health information is essential to promote patient engagement and informed participation in clinical research. Brief summaries on ClinicalTrials.gov are indented for lay people; however they are often written at a reading level that is too advanced for the public. This study evaluated the performance of a Generative Artificial Intelligence (GAI)-powered tool-Pub2Post-in producing readable and complete layperson brief summaries for urologic oncology clinical trials. Twenty actively recruiting clinical trials on prostate, bladder, kidney, and testis cancers were retrieved from ClinicalTrials.gov. For each, a GAI-generated summary was produced and compared with its publicly available counterpart. Readability indices, grade-level indicators, and text metrics were analyzed alongside content inclusion across eight structural domains. GAI-generated summaries demonstrated markedly improved readability (mean FRES 73.3 ± 3.5 vs. 17.0 ± 13.1;

Indexed as

Artificial IntelligenceClinical Trials as TopicComprehensionUrologic NeoplasmsHealth LiteracyHumansMaleartificial intelligenceclinical trialsGenerative Artificial Intelligencelay summaryLLMpatient educationPub2Postreadability

Identifiers

PMID41440224
PMCPMC12731858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.